Biotech of the Week: ThromboGenics & Therapies against Eye Disease

15/04/2016 - 2 minutes

This week, we say Auf wiedersehen to Vienna and move on to the North west. Leuven, the capital city of the Flemish Brabant province in Belgium, fairly close to the country’s capital Brussels. And it is also where ThromboGenics, our Biotech of The Week is located.

biotech_week_thrombogenics_logo

City: Leuven (Belgium)

Founded: 1998

Employees: 85 (including US)

Market cap: €117.9M (on 13/04/2016)

CEO: Patrik De Haes

thrombogenics_biotech_patrick_de_haes_vma_eye_opthalmology_jetrea

Mission: Aiming to help patients worldwide, ThromboGenics, founded in 1998, develops novelty and better treatments for several eye conditions. Their main focus is the development of therapies that meets clinical needs in Ophthalmology.

However, they also expanded their research and development range to cardiovascular and oncology programs. They have been listed on the NYSE Euronext Brussels stock exchange since 2006.

Their lead product, JETREA (aka Ocriplasmin) is the first and only FDA-approved non-surgical treatment indicated for symptomatic Vitreomacular adhesion (sVMA) and traction (VTA) –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member